LncRNA XLOC_003810 modulates thymic Th17/Treg balance in myasthenia gravis with thymoma

Imbalance of T helper 17 (Th17)/regulatory T (Treg) cells is involved in the pathogenesis of myasthenia gravis with thymoma (MG‐T). Long non‐coding RNAs (lncRNAs) are implicated in the regulation of Th17/Treg balance. This study was designed to explore the role of XLOC_003810, a novel lncRNA, in regulating the Th17/Treg balance in MG‐T. The thymic CD4+ T cells were isolated from control subjects and MG‐T patients. The Th17/Treg balance was evaluated by determining proportions of Th17 and Treg cells and expression of Th17‐ and Treg‐ associated molecules. Lentivirus‐mediated silencing and overexpression of XLOC_003810 in CD4+ T cells were performed. The results showed that XLOC_003810 expression was higher in MG‐T thymic CD4+ T cells than that in the control group. Furthermore, the ratio of Th17/Treg cells, proportion of Th17 cells and levels of Th17‐associated molecules were significantly increased, whereas the proportion of Treg cells and levels of Treg‐associated molecules were decreased in MG‐T thymic CD4+ T cells. Importantly, the Th17/Treg imbalance in MG‐T thymic CD4+ T cells was aggravated by XLOC_003810 overexpression, whereas it was attenuated by XLOC_003810 silencing. Collectively, XLOC_003810 modulates thymic Th17/Treg balance in MG‐T patients, providing the scientific basis for the clinical targeted therapy of MG‐T.

[1]  Jia Guo,et al.  Long non-coding RNA DQ786243 modulates the induction and function of CD4+ Treg cells through Foxp3-miR-146a-NF-κB axis: Implications for alleviating oral lichen planus. , 2019, International immunopharmacology.

[2]  T. Bian,et al.  LncRNA-MEG3 functions as a competing endogenous RNA to regulate Treg/Th17 balance in patients with asthma by targeting microRNA-17/ RORγt. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  Zhaojun Liu,et al.  The long noncoding RNA MALAT‐1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR‐338‐3p in myasthenia gravis , 2018, Journal of cellular biochemistry.

[4]  Huixiang Li,et al.  LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. , 2018, International journal of biological macromolecules.

[5]  Nadine Dragin,et al.  Thymus involvement in early‐onset myasthenia gravis , 2018, Annals of the New York Academy of Sciences.

[6]  Yang Wang,et al.  Sirtinol regulates the balance of Th17/Treg to prevent allograft rejection , 2017, Cell & Bioscience.

[7]  A. Evoli Myasthenia gravis: new developments in research and treatment , 2017, Current opinion in neurology.

[8]  Liqun Xu,et al.  IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis though HLA-DRB1. , 2017, Clinical immunology.

[9]  Yvonne Tay,et al.  Long noncoding RNAs: lincs between human health and disease. , 2017, Biochemical Society transactions.

[10]  W. Graninger,et al.  Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders , 2017, Molecules.

[11]  Ping Chen,et al.  Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma , 2017, Pathology & Oncology Research.

[12]  Guiyou Liu,et al.  Expression profile of long noncoding RNAs and mRNAs in peripheral blood mononuclear cells from myasthenia gravis patients , 2016, Journal of Neuroimmunology.

[13]  Jing Lin,et al.  Long non-coding RNA MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  Hong Wang,et al.  Natural killer cells regulate Th1/Treg and Th17/Treg balance in chlamydial lung infection , 2016, Journal of cellular and molecular medicine.

[15]  B. Ammori,et al.  Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients , 2016, Oncotarget.

[16]  Xiaofang Wang,et al.  Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients. , 2015, International journal of clinical and experimental pathology.

[17]  A. C. Yazici,et al.  RETRACTED ARTICLE: Impact of Toll-Like Receptors 2/3/4/9, IL-1-α/β and TNF-α Polymorphisms in Cervical Cancer Susceptibility in Tunisia , 2018, Pathology & Oncology Research.

[18]  K. Fitzgerald,et al.  Long non-coding RNAs and control of gene expression in the immune system , 2014, Trends in Molecular Medicine.

[19]  S. Berrih-Aknin,et al.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. , 2014, Journal of autoimmunity.

[20]  S. Berrih-Aknin,et al.  The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ. , 2013, Revue neurologique.

[21]  A. Marx,et al.  The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. , 2013, Autoimmunity reviews.

[22]  Wei Wang,et al.  [Thymoma T helper type 17 cells and related cytokines in myasthenia gravis]. , 2012, Zhonghua nei ke za zhi.

[23]  Z. Wang,et al.  T Helper Type 17 Cells Expand in Patients with Myasthenia‐Associated Thymoma , 2012, Scandinavian journal of immunology.

[24]  Bin Li,et al.  FOXP3 and RORγt: transcriptional regulation of Treg and Th17. , 2011, International immunopharmacology.

[25]  H. Utsumi,et al.  Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients , 2010, Journal of Neuroimmunology.

[26]  S. Ding,et al.  Reduction of natural regulatory T cells in thymomas accompanying myasthenia gravis and its possible association with Foxp3 and thymic stromal lymphopoietin , 2009 .

[27]  A. Melms,et al.  Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma , 2005, Journal of Neuroimmunology.